AbbVie
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.22 | 29 |
| neurology | ×1.50 | 5 |
| immunology | ×0.70 | 4 |
| gastroenterology | ×1.50 | 4 |
| dermatology | ×1.50 | 3 |
| ophthalmology | ×1.50 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.49 | 12 |
| phase 1 | ×1.10 | 10 |
| phase 2 | ×1.50 | 9 |
| phase 3 | ×0.92 | 9 |
| preclinical | ×1.50 | 7 |
| discovery | ×0.87 | 4 |
Strategy profile
Based on 15 disclosed transactions, AbbVie concentrates its licensing activity in Oncology, Immunology, and Neurology. AbbVie pays a 1.36x premium over market median, with the strongest premiums in Neurology (1.50x). Their most common deal structure is License, with an average disclosed value of $2.0B. Most recent activity: 2026.
Premium by therapeutic area
How AbbVie pays relative to peer medians in each TA
Pipeline coverage & gaps
AbbVie has disclosed activity in 6 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 8 | $433M | $2.6B |
| Acquisition | 3 | $2.1B | $1.9B |
| Collaboration | 2 | — | $720M |
| Option | 2 | $100M | $1.2B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | FG-M701 | FutureGen | inflammatory bowel disease | preclinical | $150M | $1.7B |
| 2026 | RC148 | RemeGen | advanced solid tumors | unknown | — | $5.6B |
| 2026 | — | Nxera Pharma | neurological diseases | discovery | — | $1.2B |
| 2026 | KST-6051 | Kestrel Therapeutics | KRAS-driven cancers | unknown | — | $1.4B |
| 2026 | HSK55718 and HSK51155 | Haisco Pharmaceutical Group | acute pain | preclinical | $30M | $745M |
| 2026 | Alveltamig | Zejing Biopharmaceutical | DLL3-positive tumors, small-cell lung cancer | unknown | $100M | $1.2B |
| 2026 | RC148 (ABBV-1480) | RemeGen Co., Ltd. | multiple advanced solid tumors | phase_1 | $650M | $5.6B |
| 2025 | Alveltamig (ZG006) | Zelgen Biopharmaceuticals | small cell lung cancer (SCLC) | phase_1 | $100M | $1.2B |
| 2025 | ZG006 (Alveltamig) | Zelgen Pharma | DLL3-expressing tumors | unknown | $100M | $1.2B |
| 2025 | ISB 2001 | Ichnos Glenmark Innovation (IGI) | relapsed/refractory multiple myeloma | phase_1 | $700M | $1.9B |
| 2025 | ABBV-RGX-314 / surabgene lomparvovec (DR amendment) | REGENXBIO | diabetic retinopathy | phase_2 | — | $200M |
| 2025 | ISB 2001 | IGI Therapeutics (Ichnos Glenmark Innovation) | oncology and autoimmune diseases | unknown | $700M | $1.9B |
| 2025 | ISB 2001 | Ichnos Glenmark Innovation (IGI Therapeutics) | relapsed/refractory multiple myeloma | phase_1 | $700M | $1.9B |
| 2025 | CPTX2309 (in vivo tLNP anti-CD19 CAR-T) | Capstan Therapeutics | autoimmune | phase_1 | $2.1B | $2.1B |
| 2025 | In vivo CAR-T platform | Capstan Therapeutics | Lupus, Myasthenia Gravis | preclinical | $2.1B | $2.1B |
How this is computed
For each AbbVie deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 51 disclosed deal premiums vs. peer medians. Raw premium 1.365, clamped to [0.7, 1.5].